Tate & Lyle signs second licence agreement with Eminate over next generation sodium reduction technology

| Filed in:

London, UK, 29 May 2013 – Tate & Lyle, a global provider of food ingredients and solutions, announces the signing of a second exclusive, worldwide licence agreement with Eminate Limited, a subsidiary of the University of Nottingham, for a hollow microsphere technology designed to reduce sodium bicarbonate in baked goods. The agreement follows the 2011 agreement between the two companies giving Tate & Lyle exclusive rights to the SODA-LO® Salt Microspheres technology.

The agreement gives Tate & Lyle exclusive rights to develop the new technology and to manufacture and commercialise ingredients derived from it. The technology is expected to eventually enable up to 50% reduction of sodium in baked good applications where sodium bicarbonate can be a greater overall contributor to sodium content than salt.

Dr John Stewart, Tate & Lyle’s Director of Open Innovation said: "We are delighted to announce our second agreement with Eminate. This new technology will help us to expand our sodium reduction offering into a wider range of categories and, while the technology is still at the development stage, the results to-date have been very encouraging. Tate & Lyle’s goal is to become the partner of choice in our sector and our new agreement with Eminate is another example of our Open Innovation approach at work, collaborating with innovative partners to develop new and exciting speciality food ingredients.”

“We are very happy to announce a second licence agreement with Tate & Lyle” said Neil Davidson, Chairman of Eminate Limited. “Our goal is to develop game-changing food ingredient technologies and to partner with global companies to commercialise them. This second agreement with Tate & Lyle demonstrates the success of this approach”.

Under the terms of the agreement, Tate & Lyle assumes responsibility for further development of the ingredient and will be responsible for commercialising the final product on a global basis including manufacturing, product development, sales and marketing.

In 2011 Tate & Lyle signed an exclusive worldwide licence agreement with Eminate for their SODA-LO® Salt Microspheres technology, which was launched globally in 2012. The industry has since recognised the innovative nature of SODA-LO® Salt Microspheres with a number of awards. In September 2012, SODA-LO® Salt Microspheres was recognised as one of the most innovative new ingredients at Food Ingredients South America. In November 2102, SODA-LO® was recognised as the "Heart Health and Circulatory Innovation of the Year", and as the overall "Most Innovative Health Ingredient of the Year" at the 2012 Nutrition & Wellness Excellence Awards.

ENDS

For more information please contact:

Mathew Wootton
Group VP, Investor & Media Relations
Tate & Lyle PLC
t: +44 (0)20 7977 6211
m: +44 (0)7500 100 320
e: [email protected]

For information regarding Open Innovation at Tate & Lyle, please contact:

Dr John Stewart
Director, Open Innovation
Tate & Lyle Innovation & Commercial Development
e: [email protected]

Agreement gives Tate & Lyle exclusive rights to Eminate’s sodium bicarbonate hollow microsphere technology for sodium reduction in baked goods Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, operating from over 30 production facilities around the world. Tate & Lyle operates through two global business units, Speciality Food Ingredients and Bulk Ingredients, supported by Innovation and Commercial Development. The Group's strategy is to become the leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving the Bulk Ingredients business for sustained cash generation to fuel this growth. Speciality Food Ingredients include starch-based speciality ingredients (corn-based speciality starches, sweeteners and fibres), no calorie sweeteners (including SPLENDA® Sucralose) and Food Systems which provides blended ingredient solutions. Bulk Ingredients include corn-based bulk sweeteners, industrial starches and fermentation products (primarily acidulants). The co-products from both divisions are primarily sold as animal feed. Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2012, Tate & Lyle sales totalled £3.1 billion. http://www.tateandlyle.com. SPLENDA® is a trademark of McNeil Nutritionals, LLC Eminate Ltd is a wholly owned subsidiary of The University of Nottingham, founded in 2006, with expertise in the design and commercial application of micro and nano particles, coatings and powders. Eminate Ltd was established with help from a grant from the government-backed Technology Strategy Board (www.innovateuk.org), which works to create economic growth by ensuring that the UK is a global leader in innovation. The business operates across a range of sectors including food & ingredients, health, pharmaceuticals, and energy storage. Novel, patented, products have already been developed within the company, and taken to first commercial sale / licence, in the food ingredients, functional foods and engineering coatings markets. Eminate’s research and development teams continue to work in close partnership with a range of companies, universities and research organisations to develop new products and provide innovative solutions to commercial challenges Eminate is based in the East Midlands with offices, research laboratory, and production facilities in Sutton Bonington and Nottingham.

About Tate & Lyle: 
Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.

Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.

Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.

Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants).  It also sells co-products from the corn milling process as animal nutrition.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2019, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or Linkedin.